Howard Horn Sells 4,653 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Howard Horn sold 4,653 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the sale, the chief financial officer directly owned 105,689 shares in the company, valued at $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Howard Horn also recently made the following trade(s):

• On Friday, May 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $24.90, for a total transaction of $116,606.70.
• On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $20.97, for a total transaction of $98,202.51.
• On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The stock was sold at an average price of $22.40, for a total transaction of $36,624.00.

Ultragenyx Pharmaceutical Trading Down 4.7%

Shares of RARE stock opened at $21.78 on Wednesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.29 and a 1 year high of $42.37. The firm’s 50 day moving average is $23.47 and its 200-day moving average is $25.71. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -3.56 and a beta of 0.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The company had revenue of $136.00 million for the quarter, compared to analyst estimates of $158.19 million. During the same quarter in the previous year, the company posted ($1.57) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was down 2.2% on a year-over-year basis. On average, equities research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the business. Assetmark Inc. lifted its holdings in Ultragenyx Pharmaceutical by 1,706.7% in the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,024 shares during the period. Huntington National Bank lifted its holdings in Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 393 shares during the period. Parallel Advisors LLC lifted its holdings in Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 1,440 shares during the period. Leonteq Securities AG lifted its holdings in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 1,333 shares during the period. Finally, Danske Bank A S acquired a new position in Ultragenyx Pharmaceutical in the third quarter valued at approximately $39,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on RARE shares. Barclays reduced their target price on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Guggenheim reduced their target price on shares of Ultragenyx Pharmaceutical from $52.00 to $43.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. Cantor Fitzgerald upped their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research report on Thursday, May 21st. Truist Financial upgraded shares of Ultragenyx Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.56.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.